A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

计划入组 452 人 · 首次发布于 2008 年 1 月 30 日

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

计划入组 347 人 · 首次发布于 2013 年 6 月 27 日

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

计划入组 24 人 · 首次发布于 2009 年 1 月 13 日

Risperidone(Perseris, Risperdal, Rykindo, Uzedy, Okedi)

C₂₃H₂₇FN₄O₂ · Rx

Pipamperone/Risperidone

LAI-006

LAI CORPORATION PTY LTD

Australia

Jilin Province Xidian Pharmaceutical SciTech Development Co.,Ltd

CTO Realty Growth

United States

Olanzapine LAI Shows Promise in Schizophrenia Treatment with Improved Safety Profile

Teva's Olanzapine LAI Shows Positive Phase 3 Results for Schizophrenia

Medincell Raises Capital to Advance Long-Acting Injectable Platform and Expand Partnerships